157 related articles for article (PubMed ID: 38402609)
21. KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
Lim TKH; Skoulidis F; Kerr KM; Ahn MJ; Kapp JR; Soares FA; Yatabe Y
Lung Cancer; 2023 Oct; 184():107293. PubMed ID: 37683526
[TBL] [Abstract][Full Text] [Related]
22. Oxidative stress-triggered Wnt signaling perturbation characterizes the tipping point of lung adeno-to-squamous transdifferentiation.
Fang Z; Han X; Chen Y; Tong X; Xue Y; Yao S; Tang S; Pan Y; Sun Y; Wang X; Jin Y; Chen H; Hu L; Hui L; Li L; Chen L; Ji H
Signal Transduct Target Ther; 2023 Jan; 8(1):16. PubMed ID: 36627278
[TBL] [Abstract][Full Text] [Related]
23. Limited role of
Li HS; Liu CM; Wang Y
Future Oncol; 2022 Jun; 18(19):2433-2443. PubMed ID: 35440164
[TBL] [Abstract][Full Text] [Related]
24. Adagrasib: a novel inhibitor for
Guo MZ; Marrone KA; Spira A; Rosner S
Future Oncol; 2023 May; 19(15):1037-1051. PubMed ID: 37133216
[TBL] [Abstract][Full Text] [Related]
25. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
Adachi Y; Ito K; Hayashi Y; Kimura R; Tan TZ; Yamaguchi R; Ebi H
Clin Cancer Res; 2020 Nov; 26(22):5962-5973. PubMed ID: 32900796
[TBL] [Abstract][Full Text] [Related]
26. Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With
Negrao MV; Spira AI; Heist RS; Jänne PA; Pacheco JM; Weiss J; Gadgeel SM; Velastegui K; Yang W; Der-Torossian H; Christensen JG; Sabari JK
J Clin Oncol; 2023 Oct; 41(28):4472-4477. PubMed ID: 37327468
[No Abstract] [Full Text] [Related]
27. Safety and Intracranial Activity of Adagrasib in Patients With
Bernstein E; Luo J; Wang K; Negrao MV; Jänne PA; Sabari JK
JCO Precis Oncol; 2024 Feb; 8():e2300447. PubMed ID: 38330263
[No Abstract] [Full Text] [Related]
28. The KRAS
Hallin J; Engstrom LD; Hargis L; Calinisan A; Aranda R; Briere DM; Sudhakar N; Bowcut V; Baer BR; Ballard JA; Burkard MR; Fell JB; Fischer JP; Vigers GP; Xue Y; Gatto S; Fernandez-Banet J; Pavlicek A; Velastagui K; Chao RC; Barton J; Pierobon M; Baldelli E; Patricoin EF; Cassidy DP; Marx MA; Rybkin II; Johnson ML; Ou SI; Lito P; Papadopoulos KP; Jänne PA; Olson P; Christensen JG
Cancer Discov; 2020 Jan; 10(1):54-71. PubMed ID: 31658955
[TBL] [Abstract][Full Text] [Related]
29. The KRAS
Briere DM; Li S; Calinisan A; Sudhakar N; Aranda R; Hargis L; Peng DH; Deng J; Engstrom LD; Hallin J; Gatto S; Fernandez-Banet J; Pavlicek A; Wong KK; Christensen JG; Olson P
Mol Cancer Ther; 2021 Jun; 20(6):975-985. PubMed ID: 33722854
[TBL] [Abstract][Full Text] [Related]
30.
Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
[No Abstract] [Full Text] [Related]
31. Inhibitors of the GTPase KRAS
Xu Q; Zhang G; Liu Q; Li S; Zhang Y
Expert Opin Ther Pat; 2022 May; 32(5):475-505. PubMed ID: 35062845
[TBL] [Abstract][Full Text] [Related]
32. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
Bungaro M; Novello S; Passiglia F
Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
[TBL] [Abstract][Full Text] [Related]
33. Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib.
Bauml JM; Li BT; Velcheti V; Govindan R; Curioni-Fontecedro A; Dooms C; Takahashi T; Duda AW; Odegaard JI; Cruz-Guilloty F; Jin L; Zhang Y; Anderson A; Skoulidis F
Lung Cancer; 2022 Apr; 166():270-278. PubMed ID: 34838325
[TBL] [Abstract][Full Text] [Related]
34. Management of
Malhotra J; Nguyen D; Tan T; Semeniuk Iii GB
Clin Adv Hematol Oncol; 2024 Mar; 22(2):67-75. PubMed ID: 38446474
[TBL] [Abstract][Full Text] [Related]
35. Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers.
Khan HY; Nagasaka M; Li Y; Aboukameel A; Uddin MH; Sexton R; Bannoura S; Mzannar Y; Al-Hallak MN; Kim S; Beydoun R; Landesman Y; Mamdani H; Uprety D; Philip PA; Mohammad RM; Shields AF; Azmi AS
Cancer Res Commun; 2022 May; 2(5):342-352. PubMed ID: 35573474
[TBL] [Abstract][Full Text] [Related]
36. KRAS-targeted therapy in the treatment of non-small cell lung cancer.
Yun J; Nakagawa R; Tham K
J Oncol Pharm Pract; 2023 Mar; 29(2):422-430. PubMed ID: 35938195
[TBL] [Abstract][Full Text] [Related]
37. Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo.
Zhang Y; Li C; Xia C; Wah To KK; Guo Z; Ren C; Wen L; Wang F; Fu L; Liao N
Cell Commun Signal; 2022 Sep; 20(1):142. PubMed ID: 36104708
[TBL] [Abstract][Full Text] [Related]
38. Adagrasib: First Approval.
Dhillon S
Drugs; 2023 Feb; 83(3):275-285. PubMed ID: 36763320
[TBL] [Abstract][Full Text] [Related]
39. Adagrasib in Advanced Solid Tumors Harboring a
Bekaii-Saab TS; Yaeger R; Spira AI; Pelster MS; Sabari JK; Hafez N; Barve M; Velastegui K; Yan X; Shetty A; Der-Torossian H; Pant S
J Clin Oncol; 2023 Sep; 41(25):4097-4106. PubMed ID: 37099736
[TBL] [Abstract][Full Text] [Related]
40. A saturation mutagenesis screen uncovers resistant and sensitizing secondary
Feng S; Callow MG; Fortin JP; Khan Z; Bray D; Costa M; Shi Z; Wang W; Evangelista M
Proc Natl Acad Sci U S A; 2022 May; 119(18):e2120512119. PubMed ID: 35471904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]